Eisai, Biogen move Alzheimer’s treatment into Phase III

Eisai and Biogen have announced that a Phase III trial has been initiated for the anti-amyloid beta protofibril antibody BAN2401, for use in patients with early Alzheimer's disease.

The news comes just days after the companies stopped two global Phase III trials of its previous Alzheimer's drug, aducanumab, after interim analyses indicated that the agent was ineffective and would not meet the primary endpoint.

Read th3 full article HERE